MAZ51

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 465275

CAS#: unknown

Description: MAZ51 is a VEGFR3 inhibitor. MAZ51 can suppress the activation of VEGFR3 induced by VEGF-C. However, it does not block VEGF-C-mediated VEGFR2 stimulation. In vitro and in vivo assays have shown that MAZ51 displays moderate antiproliferative activity and mediates cell apoptosis in multiple types of tumor cells.


Chemical Structure

img
MAZ51
CAS# unknown

Theoretical Analysis

MedKoo Cat#: 465275
Name: MAZ51
CAS#: unknown
Chemical Formula: C21H18N2O
Exact Mass: 314.1419
Molecular Weight: 314.388
Elemental Analysis: C, 80.23; H, 5.77; N, 8.91; O, 5.09

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MAZ51; MAZ 51; MAZ-51;

IUPAC/Chemical Name: (E)-3-((4-(dimethylamino)naphthalen-1-yl)methylene)indolin-2-one

InChi Key: VFCXONOPGCDDBQ-QGOAFFKASA-N

InChi Code: InChI=1S/C21H18N2O/c1-23(2)20-12-11-14(15-7-3-4-9-17(15)20)13-18-16-8-5-6-10-19(16)22-21(18)24/h3-13H,1-2H3,(H,22,24)/b18-13+

SMILES Code: CN(C)C1=C2C(C=CC=C2)=C(/C=C3C(NC4=C/3C=CC=C4)=O)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 314.388 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Park S, Kim HJ, Hwang HS, Han AR. Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia. Int J Stem Cells. 2021 Jun 30. doi: 10.15283/ijsc21083. Epub ahead of print. PMID: 34158419.

2: Yamamura A, Nayeem MJ, Muramatsu H, Nakamura K, Sato M. MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3. Front Pharmacol. 2021 Apr 20;12:667474. doi: 10.3389/fphar.2021.667474. PMID: 33959030; PMCID: PMC8093795.

3: Lv J, Yuan J, Xu CJ, Hao JQ, Qin YC, Wang XQ, Wang YF. VEGF-C/VEGFR-3/iNOS Signaling in Osteosarcoma MG63 Cells Mediates Stimulatory Effects on Human Umbilical Vein Endothelial Cell Proliferation. Chin Med Sci J. 2021 Mar 31;36(1):35-42. doi: 10.24920/003753. PMID: 33853707.

4: Li J, Chen Y, Zhang L, Xing L, Xu H, Wang Y, Shi Q, Liang Q. Total saponins of panaxnotoginseng promotes lymphangiogenesis by activation VEGF-C expression of lymphatic endothelial cells. J Ethnopharmacol. 2016 Dec 4;193:293-302. doi: 10.1016/j.jep.2016.08.032. Epub 2016 Aug 21. PMID: 27553977; PMCID: PMC5108701.

5: Lee JY, Hong SH, Shin M, Heo HR, Jang IH. Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels. Biochem Biophys Res Commun. 2016 Sep 16;478(2):733-8. doi: 10.1016/j.bbrc.2016.08.017. Epub 2016 Aug 6. PMID: 27507214.

6: Lim J, Ryu JH, Kim EJ, Ham S, Kang D. Inhibition of Vascular Endothelial Growth Factor Receptor 3 Reduces Migration of Gastric Cancer Cells. Cancer Invest. 2015;33(8):398-404. doi: 10.3109/07357907.2015.1047509. Epub 2015 Jun 26. PMID: 26115478.

7: Al-Husseini A, Kraskauskas D, Mezzaroma E, Nordio A, Farkas D, Drake JI, Abbate A, Felty Q, Voelkel NF. Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension. Pulm Circ. 2015 Mar;5(1):101-16. doi: 10.1086/679704. PMID: 25992275; PMCID: PMC4405722.

8: Park JH, Shin YJ, Riew TR, Lee MY. The indolinone MAZ51 induces cell rounding and G2/M cell cycle arrest in glioma cells without the inhibition of VEGFR-3 phosphorylation: involvement of the RhoA and Akt/GSK3β signaling pathways. PLoS One. 2014 Sep 30;9(9):e109055. doi: 10.1371/journal.pone.0109055. PMID: 25268128; PMCID: PMC4182637.

9: Lee JY, Park S, Kim DC, Yoon JH, Shin SH, Min WS, Kim HJ. A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia. J Clin Immunol. 2013 May;33(4):826-37. doi: 10.1007/s10875-013-9877-2. Epub 2013 Feb 13. PMID: 23404187.

10: Kazenwadel J, Secker GA, Betterman KL, Harvey NL. In vitro assays using primary embryonic mouse lymphatic endothelial cells uncover key roles for FGFR1 signalling in lymphangiogenesis. PLoS One. 2012;7(7):e40497. doi: 10.1371/journal.pone.0040497. Epub 2012 Jul 6. PMID: 22792354; PMCID: PMC3391274.

11: Matsuura M, Onimaru M, Yonemitsu Y, Suzuki H, Nakano T, Ishibashi H, Shirasuna K, Sueishi K. Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol. 2009 Oct;175(4):1709-21. doi: 10.2353/ajpath.2009.081139. Epub 2009 Sep 24. PMID: 19779139; PMCID: PMC2751566.

12: Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H. Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells. Cell Mol Life Sci. 2008 Sep;65(17):2740-51. doi: 10.1007/s00018-008-8314-9. PMID: 18642114.

13: Ny A, Koch M, Vandevelde W, Schneider M, Fischer C, Diez-Juan A, Neven E, Geudens I, Maity S, Moons L, Plaisance S, Lambrechts D, Carmeliet P, Dewerchin M. Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood. 2008 Sep 1;112(5):1740-9. doi: 10.1182/blood-2007-08-106302. Epub 2008 May 12. PMID: 18474726.

14: Breslin JW, Yuan SY, Wu MH. VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism. Lymphat Res Biol. 2007;5(2):105-13. doi: 10.1089/lrb.2007.1004. PMID: 17935478; PMCID: PMC3001341.

15: Breslin JW, Gaudreault N, Watson KD, Reynoso R, Yuan SY, Wu MH. Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H709-18. doi: 10.1152/ajpheart.00102.2007. Epub 2007 Mar 30. PMID: 17400713.

16: Foster RR, Satchell SC, Seckley J, Emmett MS, Joory K, Xing CY, Saleem MA, Mathieson PW, Bates DO, Harper SJ. VEGF-C promotes survival in podocytes. Am J Physiol Renal Physiol. 2006 Jul;291(1):F196-207. doi: 10.1152/ajprenal.00431.2005. Epub 2006 Mar 8. PMID: 16525158.

17: Kirkin V, Thiele W, Baumann P, Mazitschek R, Rohde K, Fellbrich G, Weich H, Waltenberger J, Giannis A, Sleeman JP. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer. 2004 Dec 20;112(6):986-93. doi: 10.1002/ijc.20509. PMID: 15386354.